NIH RADx initiative expands COVID-19 testing innovation for additional types of rapid tests

The NIH RADx initiative announced today that it has issued contract awards totaling $77.7 million to develop and manufacture 12 new rapid diagnostic tests for SARS-CoV-2, the virus that causes COVID-19. The home and point-of-care testing platforms target the need for high-performance, low-cost home tests and point-of-care tests that can potentially detect multiple respiratory infections.

Related Keywords

National Institutes Of Health ,Maryland ,United States ,New Jersey ,Monmouth Junction ,Palo Alto ,California ,Massachusetts ,Milpitas ,Franklin Lakes ,San Diego ,Waltham ,Connecticut ,Brucej Tromberg ,Los Angeles ,Santa Clara ,University Of California ,Radx Advanced Technology Platforms ,Department Of Defense ,Discovery Into Health ,National Institute Of Biomedical Imaging ,Luminostics Inc ,Biomedical Advanced Research ,Human Services ,Us Department Of Health ,Drug Administration ,Ellume United States ,Development Authority ,Technology Research Network ,Office Of The ,National Institute ,Biomedical Imaging ,Clip Health ,Rapid Acceleration ,Advanced Technology Platforms ,Underserved Populations ,Care Technology Research ,Assistant Secretary ,National Institutes ,Turning Discovery Into Health ,Covid 19 ,Infectious Diseases ,Influenza ,Point Of Care Covid 19 ,Iagnostics ,Radx Tech ,